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ABSTRACT  
Banaschewski and colleagues from the European Attention Deficit Hyperactivity Disorder (ADHD) 
Guideline Group make a number of critical comments regarding our systematic review on 
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methylphenidate for children and adolescents. In our present article we demonstrate that our trial 
selection was not flawed and that inclusion/exclusion was undertaken with scientific justification. 
Similarly, our data collection and interpretation was systematic and correct. We have followed a 
sound methodology for assessing risk of bias and our conclusions are not misleading. We 
acknowledge that different researchers might make risk of bias judgments at higher or lower 
thresholds, but we have been consistent and transparent in applying our pre-published peer-
reviewed protocol. Although we made minor errors, we have reviewed these and demonstrate that 
the effects are negligible and not affecting our conclusions. We are happy to correct such errors as 
well as to engage in debate on methodological and ethical issues. 
In terms of clinical implications, we are not advocating that clinicians or patients and their relatives 
should weight carefully risks and benefits. Clinical experience seems to suggest that there are 
people who benefit from this medication. Our systematic review does, however, raise questions 
regarding the overall quality of the methylphenidate trials.  
Keywords: Attention-deficit/hyperactivity disorder; methylphenidate; randomised clinical trials; meta-
analysis; systematic review.  
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Banaschewski and colleagues from the European Attention Deficit Hyperactivity Disorder (ADHD) 
Guideline Group make a number of critical comments regarding our systematic review on 
methylphenidate for children and adolescents.
1,2,3
 We thank for their continued interest in our 
work.
4, 5, 6 
We respond here to the critical points they raise,
1
 and we do not believe they have 
identified any reason to change the conclusions of our review.
 
 
 
Re. inappropriate selection of studies for inclusion  
Banaschewski et al. suggest that in our analyses we included trials that should have been excluded. 
This is not correct. They highlight three trials, which they cite as having used “active controls” 
whereas these are actually co-interventions used in both the methylphenidate group and in the 
control group. Such trials are eligible for inclusion in accordance with our protocol
7
 because they 
still compare “methylphenidate" with "no methylphenidate". The fact that both the 
“methylphenidate” and “no methylphenidate" arms receive an identical co-intervention does not 
invalidate the comparison of “methylphenidate” with “no methylphenidate”. If anything, the 
psychological co-intervention may reduce ADHD symptoms in each arm and this would add value 
to the comparison of the pharmacological treatment of the remaining symptoms, i.e., the 
“methylphenidate” versus “no methylphenidate” component of the intervention. Moreover, 
excluding these trials from our review would have produced only a negligible change in our results 
(a difference of 0.06 points in the standardized mean difference). 
Banaschewski et al. also claim that we included a trial that was not randomised.
8 
This is not correct. 
We received information by email from Dr. Lufi September 17
th
 2013, clarifying that this trial was 
randomised.
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The Multimodal Treatment of Attention Deficit Hyperactivity Disorder (MTA) trial is correctly 
included in accordance with our protocol.
7
 We raise doubts about the long-term benefit of 
methylphenidate. The MTA trial, which reported that beneficial effects may diminish over time, 
9, 10
  
was the only trial that met our “long duration” inclusion criteria and was therefore correctly 
included. Our sub-group analysis of teacher-rated ADHD symptoms in “short duration” trials (up to 
6 months) compared to “long duration” trials (over 6 months) showed a significant difference. The 
fact that there was only one trial included simply reflects the dearth of long-term trials of 
methylphenidate. In the clinical world, however, most patients receive methylphenidate for 
substantially longer periods than the length of existing trials.  
Randomised discontinuation trials are useful where the drug effect is known to be beneficial. 
However, we cannot yet be sure this is the case for methylphenidate so as the drug efficacy is still 
uncertain.  The correct design for further trials would there be to undertake randomised placebo - or 
active placebo (nocebo)-controlled trials to be undertaken.
11
  
Re. assessment of study quality 
Our assessment of the evidence as being ‘very low quality’ is not only based on the assessment of 
risk of bias in the included trials, but on additional factors encompassing heterogeneity, 
imprecision, indirectness of the evidence, and publication bias.
7 12 13
 We comment on this in detail 
in our review.
2 3 
 
We downgraded the quality of the included trials in the teacher-reported ADHD symptoms meta-
analysis to ‘very low quality’ because of high risk of bias and moderate heterogeneity. We have 
written in our published protocol that we would consider I
2
values between 30% to 60% as moderate 
level of heterogeneity.
7
 The downgrading for heterogeneity might be considered borderline, but we 
chose to downgrade because we think that a heterogeneity score (I
2
) of 37% may affect our 
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findings. Had we not done so, the downgrading would have become ‘low quality’, still signaling 
that one ought not to have too much confidence in the findings. The short trial duration could be the 
basis for further downgrading for indirectness according to GRADE.
 12, 13
 We did not downgrade for 
this, but arguably could have done so.  
For many years, there has been intense discussion within The Cochrane Collaboration, about the 
risk of bias due to vested interests.
14-16
 Andreas Lundh and colleagues have shown that sponsorship 
and conflict of interest affect outcomes through many subtle mechanisms.
17 
They also demonstrated 
that vested interests per se were enough to lead to overestimation of benefits and underestimation of 
harms, even when all other bias domains were assessed as being of low risk of bias.
17 
Banaschewski et al. state that our vested interest domain was inconsistently rated across the 
included trials and show some examples of this in their appendix.  Had there been inconsistencies 
regarding one domain of bias in a few trials this would not change the fact that these trials, overall, 
should still be considered as being at high risk of bias. Regarding the three trials by Barkley 1991, 
Brown 1985, and Jensen 1999 in Table 1
1
, we erroneously rated them as being of low risk of bias. 
They should have been rated as “unclear” because of the vested interest bias and we will correct this 
in the next update of our review (again, it will not materially change our results or conclusions).  
It is not incorrect for us to state that none of the trials funded by the pharmaceutical industry 
showed a low risk of bias in all other areas as we considered all the trials as high risk of bias on the 
domain of blinding because the common and well recognised adverse effects of sleep difficulties 
and appetite suppression are easily recognisable by outcome assessors. We report this clearly in our 
review. 
We contacted the authors of 161 trials twice for supplemental information, including information 
about vested interests. Only 92 responded. Based on the available evidence, we assessed 71 trials as 
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having a high risk of bias in the vested interest domain as they were funded by the industry and/or 
the authors were affiliated with the industry. We contacted Ashare et al. by email in 2013, but did 
not receive a response. However, considering that this trial was  funded by National Institute of 
Mental Health and from the National Institute on Drug Abuse, we rated it as low risk of bias on the 
vested interest domain. 
In our BMJ article, we reported that we had undertaken the risk of bias subgroup analysis, but did 
not report the result in the BMJ article as we considered all trials to be high risk of bias trials.
3
 As 
our BMJ article cross references our full Cochrane review,
 2
 the readership will locate this 
information in the full review, should they wish to. 
In placebo-controlled trials it is possible to discriminate between drugs inducing symptoms / 
adverse events and placebo on the basis of reported effects alone. This fact raises questions about 
the true blindness of such trials.
18 
Adverse events such as decreased appetite or sleep difficulties 
(and subsequent tiredness) are unsubtle and obvious, so easy detection by teachers is likely. 
On the issue of nocebo, we acknowledge that there are substantial ethical dilemmas around their 
use. Several authors have underlined the importance of the use of ‘active placebo’ (nocebo) in 
clinical trials.
18 
This is a methodological issue and we would like to stress that nocebos would need 
to first be shown to be safe in adults, and methylphenidate versus nocebo trials also shown to favour  
methylphenidate in adults.
2, 3
 Only then would  nocebo controlled trials be ethically defensible in 
children.   
 
 
Re. serious adverse effects of methylphenidate 
We agree with Banaschewski et al. that there is certainly a weakness of the available evidence of 
serious adverse events from randomised clinical trials. Based on our other protocol on 
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methylphenidate for ADHD, we are presently examining the reporting of adverse events in quasi-
randomised and observational studies.
19
 This work is not yet complete. We are not sure that the 
article by Graham et al.
20 
showing almost no adverse events, accurately reflects the evidence in this 
field and it may reflect their bias or reflect the fact that adverse events are under-reported in 
efficacy trials. 
Re. effect sizes and clinical effectiveness 
The problem is that one does not know the true magnitude of the effect size due to the very low 
quality of evidence. Therefore, it is difficult to state whether the effect size of methylphenidate 
should be favorably viewed.  
Re. errors in our primary analyses of the teacher-rated ADHD symptoms outcome  
As reported, all 19 trials were includable in accordance with our protocol.
7
 Banaschewski et al. state 
that they found errors in the imputation of data and/or sample size in seven trials. We have now 
checked these trials for errors and found that we included incorrect values in the placebo group of 
the Butter 1993 trial. We will correct this in our next review update. Again, this will not materially 
change our results or conclusions.  
When reporting end-of-period data in crossover trials in meta-analyses, it is correct to count the data 
from the pre-crossover period as well as the post-crossover if such data are available. This is not 
“double counting” as separate data exists for exposure of the participants to both placebo and active 
drug.
21
 But we did erroneously count participants twice in two crossover trials (Moshe 2012 and 
Taylor 1987) in which we only had data from the first period. We re-analysed the data accordingly 
and the standardized mean difference is now -0.78, 95% CI -0.92 to -0.64 (rather than -0.77, -0.90 
to -0.64, as originally reported); test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91), I² = 
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0%. None of the corrections leads to any noticeable changes in our results or conclusions. Anyway, 
we will correct these in an update of our review. 
Regarding the Findling 2006 trial, the authors state that: “The primary efficacy population was the 
per-protocol (PP) population defined as those subjects who received study treatment and had at least 
one efficacy measurement after the first dose, with no major efficacy protocol deviations”.22 Yes, 
we used the per-protocol population, because – as stated in the review – we conducted the analyses 
using available data.
2
 
Many of the trials had several publications. In some of these there were participant numbers that 
differed, depending on which outcome was being reported. Moreover, in some trials we had to 
compute standard deviations from standard error values and in one trial we had to calculate the 
mean difference and standard deviations from total mean difference and p value. This was due to 
data not being presented in the publications themselves and authors not providing these data. We 
received data for the first period of the crossover trial by Moshe 2012. These data are not reported 
in the published articles and it is impossible to find them in the published articles. For this reason, 
we reported in the review all the data we used for analyses.  
We appreciate these small errors being highlighted as it has given us the opportunity to reflect on 
their meaning and retest and evaluate their impact; however, they do not lead to noticeable changes 
in our results or conclusions. Please do let us know if more errors are identified and we shall correct 
any mistakes in future updates.  
 
Conclusions 
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We have demonstrated that trial selection in our review was not flawed and was undertaken with 
sufficient scientific justification. We have already responded to similar criticisms by members of 
the European ADHD Guidelines Group elswhere
4, 5, 6 
and hope that our point-by-point replies have 
helped clarify the issues further. Synthesising data from all identified 38 parallel and 147 crossover 
randomised trials comparing methylphenidate versus placebo demonstrates effects that are at best 
modest (based on external criteria for clinical significance) and limited to a very short window of 
time, i.e., less than 3 months. In terms of clinical implications, we are not advocating that clinicians 
or patients should weight if any potential benefits overpower any risks of harms. Clinical 
experience seems to suggest that there are people who benefit from this medication. Our study does, 
however, raise questions regarding the overall quality of the methylphenidate trials. These 
shortcomings have previously largely been ignored. Clinicians, parents, and children have the right 
to know this, in order to make decisions informed by the evidence.  
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